3 results
Primairy objective: Does the use of daily magnesium oxide reduce the prostate movements during a radiotherapy fraction? Secondary objectives: Does the use of magnesium oxide change the acute toxicity of the treatment? Does the use of magnesium oxide…
The primary objective is to evaluate the proportion of patients with HCV RNA below the level of quantitation (target not detected [TND] or target detected, not quantifiable [TDnq]) at 12 weeks post end of treatment (SVR12) following sofosbuvir/…
Part A1(KIN-2787 Monotherapy Escalation):Determine safety and tolerability of PO administration of Kin-2787 including DLT in participants with BRAFmutation-positive advanced or metastatic solid tumors or melanoma harboring NRAS-mutation. Identify…